A FAP‐Targeted SMDC Platform Enables Synergistic Radionuclide–Chemotherapy with PET‐Guided Evaluation

Lu-labeled conjugates produced pronounced tumor suppression (92-93% inhibition), outperforming either modality alone. Notably, the VC-linked construct showed improved tolerability relative to the GP analogue. These findings establish an imaging-guided strategy for optimizing FAP-targeted radiochemotherapeutics and identify FAP-O-VC-MMAE as a promising candidate for further translational development.